^{Photo: Seeking Alpha}

Hims & Hers Health is emerging as a focal point for investors after a fresh policy signal from U.S. health authorities hinted at a potential expansion of peptide-based therapies. The development comes at a pivotal time for the telehealth company, which is actively transitioning beyond its highly profitable compounded GLP-1 weight-loss business.

Shares of Hims & Hers climbed following comments from Health and Human Services Secretary Robert F. Kennedy Jr., who confirmed that the FDA will review peptides for possible inclusion on the 503A bulk compounding list. This designation would allow pharmacies to compound these treatments on a prescription basis, potentially opening the door to a new category of scalable offerings.

Investors Eye the Next Growth Driver Beyond GLP-1

Over the past year, compounded GLP-1 medications have served as a major revenue engine for telehealth platforms, driven by surging demand for weight-loss treatments. However, as regulatory scrutiny increases and competition intensifies from branded alternatives, investors are now looking ahead to what could replace this high-margin segment.

Peptides are quickly gaining traction as a leading candidate. While still early in adoption, they represent a broad and flexible category of therapies that could extend into areas such as metabolic health, recovery, cognitive enhancement, and anti-aging.

For Hims & Hers, the shift is not reactive but strategic. The company has been laying the groundwork for years, positioning peptides as a long-term pillar of its product ecosystem.

Building the Infrastructure for Peptide Expansion

A key milestone came in February 2025, when Hims & Hers acquired a California-based peptide manufacturing facility. The move signaled a deeper commitment to vertically integrating its supply chain and gaining early control over a market that remains largely fragmented.

CEO Andrew Dudum has described peptides as a “future-facing innovation,” highlighting their potential to unlock entirely new treatment categories. Industry estimates suggest the global peptide therapeutics market could exceed $100 billion over the next decade, driven by advances in biotechnology and personalized medicine.

Internally, the company is already exploring how to incorporate peptide therapies into its platform, particularly as it shifts users from compounded GLP-1 options toward branded medications with lower margins.

Regulatory Tailwinds Could Accelerate Adoption

The FDA’s upcoming Pharmacy Compounding Advisory Committee meeting, scheduled for July 2026, will be a critical inflection point. The review will determine whether specific peptides can be added to the 503A bulk list, a move that would legitimize their use in compounded prescriptions and bring greater regulatory clarity.

Analysts view this as a constructive step, though not an immediate catalyst for revenue. Any approvals would likely take months to materialize into commercial products, given the need for compliance, clinical validation, and physician adoption.

Still, the signal from regulators is enough to shift investor sentiment. With the stock trading around $26 and analyst price targets hovering near $25, the market appears cautiously optimistic about long-term upside tied to peptide expansion.

Balancing Opportunity With Scientific Uncertainty

Despite the enthusiasm, peptides remain a controversial space. These short chains of amino acids are being studied for a wide range of applications, but robust clinical evidence supporting many use cases is still limited.

Some compounds under consideration, such as MK-677, have faced regulatory and safety concerns and are restricted in certain contexts, including professional sports. Others, like GHK-Cu and Semax, are often marketed for cosmetic or cognitive benefits but lack large-scale clinical validation.

This creates a complex risk-reward dynamic. On one hand, the category offers massive commercial potential. On the other, it introduces regulatory, reputational, and medical uncertainties that companies must navigate carefully.

From Gray Market to Regulated Care

Hims & Hers leadership has framed the policy shift as an opportunity to bring peptide therapies into a more structured, physician-led environment. The company’s medical team has emphasized the importance of aligning any expansion with FDA guidance to ensure safety and legitimacy.

Moving peptides out of loosely regulated channels and into formal healthcare frameworks could significantly reshape the market. It would also position telehealth platforms as key distribution channels, given their ability to scale personalized treatment plans quickly.

Market Outlook and Strategic Positioning

While the FDA process is still in its early stages, the broader narrative is already taking shape. Investors are recalibrating expectations for Hims & Hers, viewing peptides not as an immediate revenue driver, but as a high-potential extension of its core business model.

If regulatory approval progresses and clinical adoption follows, peptides could evolve into a multi-billion-dollar segment within the telehealth ecosystem. For Hims & Hers, early investment in infrastructure, supply chain, and product development may offer a meaningful competitive advantage.

In the near term, volatility is likely as markets digest policy updates and clinical developments. But over the long term, the company’s ability to pivot beyond GLP-1 and capitalize on emerging treatment categories will be central to its growth story.